Off-Label Uses of Topical Ruxolitinib

Ruxolitinib cream has demonstrated significant promise in both approved and off-label dermatological indications. Its localized action, rapid symptom relief, and favourable safety profile make it an attractive alternative to systemic treatments. However, current evidence is limited by small sample sizes, short follow-up periods, and unoptimized dosing protocols. Addressing these gaps through larger-scale, long-term research will be critical to understanding its full potential as a safe and effective therapy for diverse inflammatory and autoimmune skin diseases.